The Phase II ARC-7 trial (NCT04262856) is currently investigating the combination of the anti-TIGIT domvanalimab and zimberelimab (an anti-PD-1 drug) on PD-L1-positive locally advanced or metastatic NSCLC patients. Here, CD274 is linked to non-small cell lung carcinoma.